Improving treatment for aggressive brain tumors using targeted therapies
Synergistic microglial activation and tumor cell killing for improved GBM response
This study is looking at a new treatment for glioblastoma, a tough type of brain cancer, by using a special therapy that targets cancer cells and helps the immune system fight back, with the hope of improving outcomes for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11004292 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma (GBM), a highly aggressive brain tumor, and aims to enhance the effectiveness of a novel immunotoxin therapy called D2C7-IT. The approach involves targeting specific cancer cell receptors to kill tumor cells while also addressing the immunosuppressive environment created by tumor-associated macrophages (TAMs). By activating a co-stimulatory molecule called CD40, the researchers hope to re-educate these macrophages to support the immune response against the tumor, potentially leading to better patient outcomes. The study utilizes preclinical models to evaluate the combined effects of the immunotoxin and CD40 activation.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are seeking novel treatment options.
Not a fit: Patients with other types of brain tumors or those who are not adults may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and treatment options for patients with glioblastoma.
How similar studies have performed: Other research has shown promising results using similar immunotoxin therapies and immune modulation strategies in cancer treatment.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Chandramohan, Vidyalakshmi — Duke University
- Study coordinator: Chandramohan, Vidyalakshmi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.